CLAIMS

1. Use of Compound (I):



(I)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cystic fibrosis, wherein the medicament is to be administered in an amount equivalent to 90-200 mg of Compound (I), once per day.

2. The use of claim 1, wherein the medicament is to be administered in an amount equivalent to 100 mg of Compound (I), once per day.

3. The use of claim 1 or claim 2, wherein the medicament is to be administered in an amount equivalent to 150 mg of Compound (I), once per day.

4. The use of any one of claims 1-3, wherein the medicament is to be administered orally.

5. The use of any one of claims 1-4, wherein the medicament is a tablet.

6. The use of any one of claims 1-4, wherein the medicament is a granule.

7. The use of any one of claims 1-6, wherein any atom not designated as deuterium in Compound (I) is present at its natural isotopic abundance.

8. The use of any one of claims 1-7, wherein the medicament is to be administered orally concurrently with, prior to, or subsequent to one or more second therapeutic agents.

9. The use of claim 8, wherein the second therapeutic agent is an agent useful in the treatment of cystic fibrosis.

10. The use of claim 8 or 9, wherein the second therapeutic agent is VX-809 (lumacaftor) or VX-661 (tezacaftor).

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and 90-200 mg of Compound (I):



(I)

or a pharmaceutically acceptable salt thereof.

12. The pharmaceutical composition of claim 11, comprising 100 mg of Compound (I).

13. The pharmaceutical composition of claim 11, comprising 150 mg of Compound (I).

14. The pharmaceutical composition of any one of claims 11-13, wherein the pharmaceutical composition is suitable for oral administration.

15. The pharmaceutical composition of any one of claims 11-14, wherein the pharmaceutical composition is a tablet.

16. The pharmaceutical composition of any one of claims 11-14, wherein the pharmaceutical composition is a granule.

17. The pharmaceutical composition of any one of claims 11-16, wherein the composition is suitable for oral administration concurrently with, prior to, or subsequent to one or more second therapeutic agents.

18. The pharmaceutical composition of any one of claims 17, wherein the second therapeutic agent is an agent useful in the treatment of cystic fibrosis.

19. The pharmaceutical composition of claim 17 or 18, wherein the second therapeutic agent is VX-809 (lumacaftor) or VX-661 (tezacaftor).